Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin Aet al.(2024) Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial Lancet(in press) DOI 10.1016/S0140-6736(24)00317-9, PubMed 38521086
Bjerre Trent PK, Nordskar NJ, Wangen KR, Engeskaug MI, Opheim MLØ, Aune G, Staff AC, Thorsen L, Falk RS, Eriksson AGZ(2024) Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80] Gynecol Oncol, 183, 7-8(in press) DOI 10.1016/j.ygyno.2024.02.026, PubMed 38484693
Fotopoulou C, Eriksson AG, Baiocchi G, Zivanovic O(2024) Surgery for gynecological cancers in the era of personalized medicine: a novel paradigm Int J Gynecol Cancer, 34(3), 351 DOI 10.1136/ijgc-2024-005299, PubMed 38438173